Showing 3721-3730 of 6978 results for "".
- Analysis: Deucravacitinib Shows Sustained Efficacy and Safety Over Four Yearshttps://practicaldermatology.com/news/analysis-deucravacitinib-shows-sustained-efficacy-and-safety-over-four-years/2466961/A new analysis suggested that deucravacitinib showed acceptable safety and efficacy over the course of 4 years of treatment. The POETYK PSO-1 and PSO-2 trials, upon which the analysis was based, randomized patients in (1:2:1) to receive placebo, deucravacitinib 6 mg once daily (QD), or a
- Study Highlights Gaps in Dermatology PA Certification Exam Coveragehttps://practicaldermatology.com/news/research-highlights-gaps-dermatology-pa-certification-exam-coverage/2466960/New research suggests that the prevalence of skin disease burden in the United States generally aligns with the physician assistant (PA) certification exam, with areas for improvement. According to the new study published in the Journal of Dermatology Physicians Assistants, the National C
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areatahttps://practicaldermatology.com/news/equillium-announces-positive-topline-data-phase-2-study-eq101-alopecia-areata/2466936/Equillium announced positive topline data from its phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA). The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101, as well as
- New Image-Guided Dermatology Therapy System Receives CE Mark in Europehttps://practicaldermatology.com/news/new-oncology-and-dermatology-device-approved-europe/2463232/Ultrasound tech manufacturer TOOsonix A/S announced that it has received EU Medical Device Regulation (MDR) CE certification for its image-guided dermatologic therapy system, System ONE-M™, according to a news release from the company. The device facilitates the treatment of common skin c
- Survey Shows Low Awareness, High Risk of Actinic Keratosis from Sun Exposurehttps://practicaldermatology.com/news/survey-shows-low-awareness-high-risk-actinic-keratosis-sun-exposure/2463197/A recent survey conducted by Almirall showed gaps in public awareness about actinic keratosis (AK) and the associated risks of sun exposure. The survey, which included more than 2,500 participants aged 35 and older from Spain, Germany, Italy, the United Kingdom, and the United States, rev
- Antihypertensive Drugs Linked to Increased Eczema in Elderlyhttps://practicaldermatology.com/news/antihypertensive-drugs-linked-increased-eczema-elderly/2463140/New research suggests that increased use of antihypertensive medications is associated with an increase in eczematous dermatitis. Researchers conducted a longitudinal cohort study in a population-based sample from primary care practices in The Health Improvement Network in the United Kingd
- Reflections on the “Clearly Me” Psoriasis Exhibithttps://practicaldermatology.com/news/reflecting-on-clearly-me-psoriasis-exhibit-a-qa-with-lindsay-adler/2463137/The “Clearly Me” exhibit in New York, New York, held from May 16-18, showcased real psoriatic patients through dynamic photographic portraits, captured by photographer L
- PHOTOS: "Clearly Me" NYC Event Highlights Psoriasis Journeys of Patientshttps://practicaldermatology.com/news/photos-clearly-me-nyc-event-highlights-psoriasis-journeys-patients/2463107/AbbVie recently held a dynamic, photo-centric event at High Line Nine Galleries in New York City highlighting the psoriasis journeys of several patients through photographs. The exhibit, called Clearly Me, aimed to raise awareness about psoriatic disease by telling the stories of these p
- Study: Apremilast Efficacy Shows Efficacy in Psoriasishttps://practicaldermatology.com/news/study-apremilast-efficacy-shows-efficacy-psoriasis/2463053/Results from a recent analysis suggest promise for apremilast, which showed efficacy in the treatment of patients with moderate-to-severe psoriasis. Authors publishing in Acta Dermato-Venereologica focused on the impact on skin lesions, pruritus, and serum cytokine levels. The r
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w